Analysing properties of proteasome inhibitors using kinetic and X-ray crystallographic studies

Methods in Molecular Biology

Volumn 832, Issue , 2012, Pages 373-390

  Gallastegui, Nerea ^a   Groll, Michael ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cancer; Crystallography; Drug design; Inhibitors; Kinetic studies; Proteasome

Indexed keywords

ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; BORTEZOMIB; CARFILZOMIB; CEP-18770; DELANZOMIB; DRUG DERIVATIVE; ENZYME INHIBITOR; LACTONE; OLIGOPEPTIDE; PROTEASOME; PYRAZINE DERIVATIVE; PYRROLE DERIVATIVE; SALINOSPORAMIDE A; THREONINE;

ARTICLE; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; GENETICS; METABOLISM; METHODOLOGY; MULTIPLE MYELOMA; SACCHAROMYCES CEREVISIAE; X RAY CRYSTALLOGRAPHY;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; ENZYME INHIBITORS; LACTONES; MULTIPLE MYELOMA; OLIGOPEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; PYRROLES; SACCHAROMYCES CEREVISIAE; THREONINE;

EID: 84858217350     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-61779-474-2_26     Document Type: Article

References (31)

1. Gallastegui N, Groll M (2010) The 26S proteasome: Assembly and function of a destructive machine. Trends Biochem Sci . 35 :634-642.
2. Borissenko L, Groll M (2007) 20S proteasome and its inhibitors: Crystallographic knowledge for drug development. Chem Rev 107 , 687-717.
3. Groll M, Huber R, Moroder L (2009) The persisting challenge of selective and specifi c proteasome inhibition. J Pept Sci 15 , 58-66.
4. Kisselev AF, Goldberg AL (2001) Proteasome inhibitors: From research tools to drug candidates. Chem. Biol. 8 , 739-758.
5. Groll M, Ditzel L, Lowe J, et al (1997) Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 386 , 463-471.
6. Löwe J, Stock D, Jap B, et al (1995) Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. Science 268 , 533-539.
7. Adams J, Palombella VJ, Elliott PJ (2000) Proteasome inhibition: A new strategy in cancer treatment. Invest New Drugs 18 , 109-121.
8. Richardson PG, Barlogie B, Berenson J, et al (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348 , 2609-2617.
9. Mikhael JR, Belch AR, Prince HM, et al (2009) High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. Br J Haematol 144 , 169-175.
10. Argyriou AA, Iconomou G, Kalofonos HP (2008) Bortezomib-induced peripheral neuropathy in multiple myeloma: A comprehensive review of the literature. Blood 112 , 1593-1599.
11. Groll M, Berkers CR, Ploegh HL, Ovaa H (2006) Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure 14 , 451-456.
12. Feling RH, Buchanan GO, Mincer TJ, et al (2003) Salinosporamide A: A highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora. Angew Chem Int Ed Engl 42 , 355-357.
13. Groll M, Huber R, Potts BC (2006) Crystal Structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in Complex with the 20S Proteasome Reveal Important Consequences of beta-Lactone Ring Opening and a Mechanism for Irreversible Binding. J Am Chem Soc 128 , 5136-5141.
14. Parlati F, Lee SJ, Aujay M, et al (2009) Carfi lzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 114 , 3439-3447.
15. de Bettignies G, Coux O (2010) Proteasome inhibitors: Dozens of molecules and still counting. Biochimie 92 , 1530-1545.
16. Groll M, Gotz M, Kaiser M, et al (2006) TMC- 95-based inhibitor design provides evidence for the catalytic versatility of the proteasome. Chem Biol 13 , 607-614.
17. Groll M, Schellenberg B, Bachmann AS, et al (2008) A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism. Nature 452 , 755-758.
18. Groll M, Koguchi Y, Huber R, Kohno J (2001) Crystal structure of the 20S proteasome:TMC- 95A complex: A non-covalent proteasome inhibitor. J Mol Biol 311 , 543-548.
19. Groll M, Gallastegui N, Marechal X, et al (2010) 20S Proteasome Inhibition: Designing Non-Covalent Linear Peptide Mimics of the Natural Product TMC-95A. ChemMedChem 5:1701-1705.
20. Dahlmann B, Kopp F, Kuehn L, et al (1986) Studies on the multicatalytic proteinase from rat skeletal muscle. Biomed Biochim Acta 45 , 1493-1501.
21. Groll M, Bajorek M, Kohler A, et al (2000) A gated channel into the proteasome core particle." Nature Structural Biology. Nature Structural Biology 7 , 1062-1067.
22. Lesslie AG (1994) Mosfi lm user guide, mosfi lm version 5.2. MRC Laboratory of Molecular Biology , Cambrige, UK.
23. Kabsch W (1993) Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J Appl Cryst 26 , 795-800.
24. Potterton E, Briggs P, Turkenburg M, Dodson E (2003) A graphical user interface to the CCP4 program suite. Acta Crystallogr D Biol Crystallogr. 59 , 1131-1137.
25. Brünger A, Adams P, Clore G, et al (1998) Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr. 1 , 905-921.
26. Murshudov GN, Vagin AA, Dodson EJ (1997) Refi nement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53 , 240-255.
27. Turk D (1992) Improvement of a program for molecular graphics and manipulation of electron densities and its application for protein structure determination. Thesis , Technische Universitaet Muenchen.
28. Emsley P, Lohkamp B, Scott WG, Cowtan K (2010) Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66 , 486-501.
29. Groll M, Huber R (2004) Inhibitors of the eukaryotic 20S proteasome core particle: A structural approach. Biochim Biophys Acta 1695 , 33-44.
30. Borissenko L, and Groll M (2007) Diversity of proteasomal missions: Fi ne tuning of the immune response. Biol Chem 388 , 947-955.
31. Brünger AT (1992) Free R value: A novel statistical quantity for assessing the accuracy of crystal structures. Nature 355 , 472-475.